Eos Energy CAO, Puri, sells $103k in EOSE stock
Investing.com -- Novavax (NASDAQ:NVAX) stock rose 5% after the company announced positive preclinical results for its H5N1 avian influenza vaccine candidate, showing strong immune responses in nonhuman primates.
The biotech company’s vaccine candidate, which uses Novavax’s recombinant protein-based nanoparticle technology and Matrix-M adjuvant, demonstrated immunogenicity against currently circulating H5N1 variants following either single or two-dose administration. The peer-reviewed results were published in Nature Communications.
Data from the study revealed that a single dose administered either intranasally or intramuscularly induced neutralizing antibody responses at or above levels generally considered protective. The vaccine candidate also elicited broad antibody responses, suggesting potential protection against forward-drift variants of currently circulating H5N1 virus strains.
"These preclinical results underscore the promise and potential of our pandemic influenza program as well as the strength of our technology platform and our ability to deliver against our corporate growth strategy," said Ruxandra Draghia-Akli, Executive Vice President and Head of Research and Development at Novavax.
The company highlighted that the potential for a single-dose administration, either intranasally or intramuscularly, could differentiate Novavax’s vaccine in pandemic emergency preparedness efforts.
H5N1, a highly pathogenic avian influenza virus, has caused 70 confirmed human cases in the U.S. and one death. As part of its growth strategy, Novavax plans to pursue funding, partnership, and licensing opportunities for its H5N1 vaccine candidate.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.